Cayman Chemical Company supplies scientists worldwide with the resources necessary for advancing human and animal health. We manufacture high quality biochemicals, assay kits, antibodies, and recombinant proteins and offer contract services for custom chemical synthesis/analysis, assay development/screening, and drug discovery.
Employees: 201-500
Founded date: 1980
Investors 1
| Date | Name | Website |
| - | BroadOak C... | broadoak.c... |
Mentions in press and media 11
| Date | Title | Description |
| 22.08.2024 | Cayman and Certest Announce Partnership, Expanding Access to Ionizable Lipids for Lipid Nanoparticles | Cayman and Certest Announce Partnership, Expanding Access to Ionizable Lipids for Lipid Nanoparticles Cayman Chemical and Certest Pharma have announced a new partnership to make Certest ionizable lipids available for LNP research through Ca... |
| 06.06.2024 | Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com | qPCR-based assays for infectious diseases Cayman partnered with PCRassays.com to widen their portfolio of molecular-based detection kits. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of which are mul... |
| 11.03.2024 | L-Ergothioneine (EGT) Market Size, Share, Trends, Growth And Regulatory Landscape By 2024-2031 | AnaSpec, Inc. | L-Ergothioneine (EGT) Market Global L-ergothioneine (EGT) market is projected to grow from US$ 40.8 Mn in 2023 to US$ 389.3 Mn by 2030, at a compound annual growth rate (CAGR) of 38%. BURLINGAME, CALIFORNIA, UNITED STATES, March 11, 2024 /E... |
| 20.02.2024 | Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies | cayman logo Cayman Chemical introduces the latest addition to the company's portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue... |
| 11.07.2023 | Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics | navinci-cayman-spacial-proteomics "We are excited that, by adding the Navinci product line to our catalog, we can help researchers discover breakthroughs and uncover new therapies," said Karin Dunbar, Director of Marketing at Caym... |
| 27.04.2023 | New Traceable Opioid Material® Kit Expands Coverage to Other Emerging Drugs of Concern in Seized Samples and Toxicological Casework | Fentanyl Analog Screening Kits “We anticipate that the expanded drug coverage offered by these panels will help quickly identify emerging drug trends, resolve forensic and clinical toxicology casework, and improve drug surveillance efforts,... |
| 15.12.2022 | CABRI Awards $40,000 in Fellowships to Ten Undergraduate Researchers | 2022 CABRI Fellowship Recipients “These fellowships provide a valuable opportunity to undergraduates by allowing them to focus on gaining laboratory experience that builds their scientific talent,” said Kourtney Goode, Ph.D., Academic Relat... |
| 23.09.2021 | Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration | This stable, prepackaged, ready-to-use, flexible, and easily-fitted osseointegration accelerant would augment the bone’s natural repair process, facilitating earlier implant loading and decreasing the number of implant failures. ANN ARBOR, ... |
| 21.09.2021 | Cayman Offers Multidisciplinary Lipid-Based Drug Delivery Capabilities | This triad partnership provides Cayman clients a one-stop shop for lipid nanoparticle development—from R&D to final formulation. ANN ARBOR, Mich. (PRWEB) September 21, 2021 Cayman Chemical, leader in the synthesis, purification, and cha... |
| 13.07.2021 | INDIGO Biosciences Expands Portfolio to Include Cannabinoid Type 1 Receptor | CB1R represents an exciting expansion for our team in both technology and our understanding of the role cannabinoid receptors play in the critical disease states in which our customers work, including oncology and neurological disorders. ST... |
Show more